The relationship between cognitive impairment and symptomatic convergence insufficiency in Parkinsonian disorders has not been previously investigated.
Convergence insufficiency (CI) in Parkinsonian disorders causes disabling visual symptoms during close-up work or reading, usually manifesting as double or blurred vision; these vision problems are more common in patients who report cognitive symptoms. The relationship between cognitive impairment and symptomatic convergence insufficiency in Parkinsonian disorders has not been previously investigated. Researchers recently sought to determine if symptomatic CI, as opposed to asymptomatic CI, could serve as a marker of Parkinson cognitive impairment.
Twenty-four patients—18 with Parkinson, 5 with progressive supranuclear palsy, and 1 with multiple system atrophy—were included. Researchers collected objective findings of convergence insufficiency on neuro-ophthalmologic examination and recorded subjective visual symptoms and cognitive complaints. Objective measures included a near point of convergence (NPC) of ≥10 cm or a near/distance disparity of ≥10 prism diopters of an exotropia. The presence of CI, the NPC in centimeters, and subjective reports of visual symptoms were recorded from the medical record. The Self-Administered Gerocognitive Examination was used as a global cognitive screening measure.
Most (70.8%) had visual symptoms attributed to CI (n = 17); the rest (n = 7) had asymptomatic CI with visual complaints due to other causes (eg, exotropia, saccadic deficiency, dry eye). Three-quarters reported subjective cognitive complaints and 54.1% met SAGE criteria for cognitive impairment (total score <17).
Logistic regression models demonstrated no significant relationship between symptomatic CI status and cognitive impairment (P = .29). However, there was a significant relationship between NPC and cognitive impairment, using linear regression, even when controlling for age, education, and disease duration (P = .038). NPC was greater for those with cognitive impairment (x = 18.4 cm), compared to those who were cognitively intact (x = 12.5 cm, P = .003).
The group had lived with the diseases for a mean of 9.1 years at the time of chart review and were at higher risk of cognitive impairment, but the researchers noted there was no significant difference in disease duration between those who were cognitively impaired and those who were not.
The authors wrote that clinicians should suspect cognitive impairment in patients with objective findings of CI, whether symptomatic or not. The severity of CI may serve as an additional marker for cognitive impairment in Parkinsonian conditions, separate from age, and disease duration, and there may be a shared mechanism of dysfunction that deserves further research, they said.
Reference
Holden SK, Van Dok E, Pelak VS. Co-occurrence of convergence insufficiency and cognitive impairment in parkinsonian disorders: A pilot study [published online August 9, 2019]. Front Neurol. doi: 10.3389/fneur.2019.00864
Major Study Expands in Hopes to Cure Parkinson Disease
April 19th 2022April is Parkinson’s Disease Awareness month, and on this episode of Managed Care Cast, we take a look at the Parkinson's Progression Markers Initiative (PPMI), a study from the Michael J. Fox Foundation for Parkinson's Research (MJFF). The multicenter, international study aims to end Parkinson disease, which is expected to double worldwide by 2040, to more than 14 million people.
Listen
PD Worsens QOL, Increases Depression in Men More Than Women in the Southeast
February 17th 2023The southeastern areas of the country have worse health outcomes and health-related quality of life (HRQOL) compared with other parts of the United States, with high rates of diabetes, obesity, cancer, and cardiovascular disease.
Read More
An Inside Look at Innovations by MJFF to Assist the Parkinson Community Amid the COVID-19 Pandemic
May 26th 2020On this episode of Managed Care Cast, we speak with Rachel Dolhun, MD, vice president of Medical Communications at The Michael J. Fox Foundation for Parkinson Research, about recent innovations by The Michael J. Fox Foundation to assist patients and families of patients with Parkinson disease in adjusting to this new normal.
Listen